TABLE 2:
Characteristics of 299 Patients and 427 MRI Examinations
| Feature | Value |
|---|---|
|
| |
| Patient | |
| Age at MRI examination (y) | 48.8 (23–78) |
| Carrier of BRCA1 mutation | 140/299 (47) |
| Carrier of BRCA2 mutation | 146/299 (49) |
| Carrier of both BRCA1 and BRCA2 mutations | 6/299 (2) |
| MRI examinations | |
| Normal (i.e., no finding) | 263/427 (62) |
| Benign finding | 243/427 (57) |
| Malignant finding | 20/427 (5) |
| Examinations with benign finding | |
| Histopathology reference standard | 26/243 (11) |
| Benign breast parenchyma and sclerosing adenosis | 14/26 (54) |
| Fibrocystic changes | 1/26 (4) |
| Fibroadenomatoid change or fibroadenoma | 3/26 (12) |
| Pseudoangiomatous hyperplasia | 2/26 (8) |
| Lymph node | 1/26 (4) |
| Ductal hyperplasia | 1/26 (4) |
| Granulomatous changes | 1/26 (4) |
| Atypical ductal hyperplasia | 1/26 (4) |
| Lobular carcinoma in situ | 1/26 (4) |
| Papilloma | 1/26 (4) |
| Imaging follow-up reference standard | 217/243 (89) |
| Examinations with malignant finding (histopathology reference standard) | 20/20 (100) |
| Invasive ductal carcinoma | 11/20 (55) |
| Ductal carcinoma in situ | 8/20 (40) |
| Mixed, invasive ductal carcinoma and ductal carcinoma in situ | 1/20 (5) |
Note—Except for age (mean with range in parentheses), values are counts with percentage in parentheses.